



News Release

Suven's net up by 50%, Spends 17% of Revenue on R&D

HYDERABAD, INDIA (October 31, 2008) – SUVEN LIFE Sciences Limited is a biopharmaceutical company specializing in Central Nervous System diseases, today announced its unaudited financial results for the quarter ended Sep 2008. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on Oct 31, 2008 at Hyderabad

Financial Highlights for the Second qtr ended Sep 2008

Growth in PAT	318%	(Rs 48.3 mil vs. Rs 11.6 mil)
Growth in EBIDTA	204%	(Rs 84.3mil vs. Rs 27.7 mil)
Growth in revenue	31%	(Rs 39.1mil vs. Rs 29.9 mil)

The revenues for the half year ended Sept 2008 stood at Rs.714.3 mil compared to Rs. 588.9 mil for the corresponding previous period, registering a growth of 21%. PAT for the half year stood at Rs. 64.3 mil compared to Rs. 43.1mil for the corresponding previous period, a raise of 50%.

Suven's major thrust on innovative R&D in Drug Discovery continues with a total spending of Rs 135 mil for this half year constituting 19% of revenue with a revenue expenditure of Rs 121 mil recording about 17% of revenue for the half year.

Suven's clinical candidate SVN-502 targeted for cognition in Alzheimer's and Schizophrenia has entered the next stage of Phase 1 clinical development with the commencement of multiple ascending dose study from October 2008, which will be completed by end of 2008. SUVN-502 has attracted many big pharma from USA, Europe and Japan who would like to partner with Suven for development and commercialization.

Suven Life Sciences is a Hyderabad based Biopharmaceutical Company; a Collaborative Research Partner (CRP) since 2006 in Drug Discovery for global pharma major, is a pioneer in Contract Research and Manufacturing Services (CRAMS) since 1995 and Drug Discovery Development Support Services (DDDSS) since 2005. Suven has been involved in development of path breaking technologies for global pharma companies for more than a decade.

Suven has R&D strength of more than 300 professionals with the state of the art infrastructure for Drug Discovery and development and Clinical Research activities and the front end project management services from New Jersey and clinical research services from North Carolina, USA. For more information on Suven/ACT, please visit our Web site at <http://www.suven.com>.

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;